Seminars in Hematology
Volume 47, Issue 3 , Pages 274-280 , July 2010

Thrombocytopenia in Patients With Myelodysplastic Syndromes

References 

  1. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73:405–410
  2. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002;136–161
  3. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1–16
  4. Kouides PA, Bennett JM. Understanding the myelodysplastic syndrome. Oncologist. 1997;2:389–401
  5. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187–200
  6. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705–1714
  7. Doll DC, List AF. Myelodysplastic syndromes. West J Med. 1989;151:161–167
  8. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes (A statement from the Italian Society of Hematology). Haematologica. 2002;87:1286–1306
  9. Mittelman M, Sokolover N, Zeidman A, Redlich O, Cohen A, Fradin Z. Platelet aggregation and its clinical significance in the myelodysplastic syndromes. Leuk Res. 1999;23(suppl 1):s24
  10. Kezuka T, Usui N, Suzuki E, Wakasugi K, Usui M. Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol. 2005;49:377–383
  11. Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol. 1994;87:205–208
  12. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440
  13. Powell BL, Capizzi RL, Jackson DV, et al. Low dose Ara-C for patients with myelodysplastic syndromes. Leukemia. 1988;2:153–156
  14. Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol. 1997;20:189–192
  15. Picozzi VJ, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol. 1986;4:589–595
  16. Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer. 2003;98:2410–2419
  17. Lee ST, Jang JH, Suh HC, Hahn JS, Ko YW, Min YH. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2001;68:237–245
  18. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953–959
  19. Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Res. 1989;9:893–896
  20. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141–148
  21. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol. 2000;37:3–10
  22. Besa EC, Woermann U. Myelodysplastic syndrome (eMedicine). http://www.emedicine.com/med/topic2695.htm2006;
  23. Consensus conference. Platelet transfusion therapy. JAMA. 1987;257:1777–1780
  24. Sepulveda JL. Alloimmunization from transfusions. emedicine.medscape.com2005;
  25. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion. 1997;37:624–630
  26. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000;64:251–256
  27. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493–1499
  28. Wolkers WF, Walker NJ, Tablin F, Crowe JH. Human platelets loaded with trehalose survive freeze-drying. Cryobiology. 2001;42:79–87
  29. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  30. Kantarjian H, Issa J-PJ, Rosenfeld C, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1794–1803
  31. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465
  32. Cermak J, Belickova M, Michalova K. Combined immunosuppressive treatment in patients with early myelodysplasia. Haematologica. 2005;90(Suppl 2):357
  33. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res. 2004;28:1177–1180
  34. Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M.D (Anderson Cancer Center experience). Ann Oncol. 2005;16:139–145
  35. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165–4172
  36. Neumega (oprelvekin) prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals; 2006;
  37. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995;85:3066–3076
  38. Li J, Yang C, Xia Y, Bertino A, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248
  39. Urabe A, Komatsu N, Okomoto T, et al. Effects of pegylated recombinant human megakaryocyte growth and developement factor on haematopoiesis in patients with aplastic anemia and myelodysplastic syndrome. Exp Hematol. 2001;29:112
  40. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–2602
  41. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673–681
  42. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–368
  43. Sekeres M, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS) [abstract]. J. Clin. Oncol. 2009;27(15S):7009
  44. Kantarjian H, Pierre Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28:437–444
  45. Kantarjian H, Giles F, Greenberg P, et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract]. ASH Annual Meeting Abstracts. 2008;112:224
  46. Greenberg PL, Garcia-Manero G, Moore MR, et al. Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract]. ASH Annual Meeting Abstracts. 2009;114:1769
  47. Lyons RM, Larson RA, Kosmo MA, et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving Lenalidomide [abstract]. ASH Annual Meeting Abstracts. 2009;114:1770
  48. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899–3908

PII: S0037-1963(10)00031-4

doi: 10.1053/j.seminhematol.2010.02.006

Seminars in Hematology
Volume 47, Issue 3 , Pages 274-280 , July 2010

Article Tools